Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
Page 2

Furthermore, it is also noted that suitable bioequivalence methods are lacking for many generic ophthalmic formulations, including suspensions and emulsions. Therefore an investigation of the relationship between various physicochemical properties and their effect on ocular bioavailability will help the FDA in establishing guidelines for the determination of bioequivalence of ophthalmic suspensions and emulsions.

The scope of the program will cover two types of inquiries:

a) In vitro study – Formulations with different physicochemical properties are manufactured using a selected steroid and characterized in vitro. Drug release and stability tests are conducted to understand how differences in physicochemical properties may affect ocular bioavailability.

b) In vivo study – Formulations selected based on the results of the in vitro study are tested in an animal model. A pharmacokinetic study should be conducted by assessing the ocular distribution of the steroid in various eye tissues and organs at various time points.

In order to support these initiatives, the Food and Drug Administration is set to administer funds in the amount of $400,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The United States Department of Health and Human Services, the mother agency funding the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program, is country's premiere agency for protecting the health of all Americans and providing essential human services, especially to those who medically challenged and vulnerable.

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Grand Challenges in Global Mental Health: Integrating Mental Health into Chronic Disease Care Provision in Low- and Middle-Income Countries
The National Institutes of Health has recently formed a partnership with the National Institute of Mental Health (NIMH) in order to establish the Grand Challenges in Global Mental Health: Integrating Mental Health into Chronic Disease Care Provision in Low- and Middle-Income Countries Program.

---

Pilot Studies of Innovative Treatments in Mental Disorders Project
The National Institutes of Health has recently collaborated with the National Institutes of Mental Health (NIMH) to establish the Pilot Studies of Innovative Treatments in Mental Disorders Program.

---

Strategic Alliances for Medications Development to Treat Substance Use Disorder Program
The National Institutes of Health, in cooperation with the National Institute on Drug Abuse (NIDA), has recently established the Strategic Alliances for Medications Development to Treat Substance Use Disorder Program wherein both agencies seek to support the development of substance abuse drugs by leveraging the strengths of two or more organizations toward a common goal of medications development.

---

Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program
In keeping with this mission, the National Institutes of Health has partnered with the Canadian Institutes of Health Research (CIHR), the National Heart, Lung, and Blood Institute (NHLBI), and the Institute of Circulatory and Respiratory Health (ICRH) to establish the Core Clinical Centers for the Cardiothoracic Surgical Trials Network Program.

---